Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03718429 · ClinicalTrials.gov registry record · Phase 4
Pharmacodynamic Effects of Low-dose Rivaroxaban With Antiplatelet Therapies
A Phase 4 study, sponsored by University of Florida.
- Completed
- Registry status
- Phase 4
- Development phase
- 86
- Enrollment target
NCT03718429 is a Phase 4 study that has completed, run by University of Florida. The registered enrollment target is 86 participants.
The verdict
NCT03718429, a Phase 4 study, has completed, sponsored by University of Florida.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 86 participants
- Enrollment target
Study Summary
Recent studies indicate that anti-factor-Xa inhibition with low-dose rivaroxaban may have a role in the reduction of ischemic recurrences in patients with atherosclerotic disease manifestations. To date there is very little data, and not conducted in human subjects, on the interplay between anti-Xa blockade with low-dose rivaroxaban and antiplatelet therapies, and in particular how this affects profiles of platelet reactivity and thrombin generation. Given the potential role for the use of low-dose rivaroxaban for the prevention of ischemic recurrences in patients with atherothrombotic disease manifestations, including coronary artery disease (CAD) and peripheral arterial disease (PAD), the study team proposes a prospective pharmacodynamic (PD) investigation assessing the impact of low-dose rivaroxaban when used in combination with antiplatelet treatment regimens commonly used in clinical practice.
Interventions
- DRUG Rivaroxaban 2.5 mg Tablet
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 86 participants |
| Start Date | 2019-01-14 |
| Est. Completion | 2020-08-30 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03718429
The ClinicalTrials.gov registry entry for NCT03718429 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 86 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Florida, which has 1,106 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Rivaroxaban 2.5 mg Tablet is the first listed.
NCT03718429 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03718429 about?
NCT03718429 is a clinical study titled "Pharmacodynamic Effects of Low-dose Rivaroxaban With Antiplatelet Therapies". Recent studies indicate that anti-factor-Xa inhibition with low-dose rivaroxaban may have a role in the reduction of ischemic recurrences in patients with atherosclerotic disease manifestations. To date there is very little data, and not conducted in human subjects, on the interplay between anti-Xa...
What is the current status of trial NCT03718429?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 86 participants. The study started on 2019-01-14. Estimated completion is 2020-08-30.
What interventions are being tested in trial NCT03718429?
The interventions under investigation include: Rivaroxaban 2.5 mg Tablet (DRUG).
Who is sponsoring clinical trial NCT03718429?
This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.